Based on the linked source; automatically prepared and checked against the original report.
Funding breakdown
Emerald has raised an additional £1.4 million, bringing total funding to £2.9 million. The round comprises a £700,000 Innovate UK grant and £700,000 in venture capital investment. Existing investors participated alongside new backers Sequel and Highgoal, while Emerald’s valuation increased from its previous funding round.
Platform and clinical model
Emerald combines in-clinic laboratory screening with a digital platform that brings together test results, wearable information and health history. The company says members are paired with a GP who can diagnose, prescribe and refer into private or NHS care where appropriate. Emerald is Care Quality Commission registered and its platform is authorised as a UKCA Class I medical device by the MHRA.
Expansion plans and reported progress
The funding will support commercial expansion, product development and clinical services, with Emerald targeting one million members over the next three years. Innovate UK’s grant is earmarked for AI applications and underlying technology. Emerald says its member base has grown tenfold since the start of 2026 and that it has processed more than 100,000 laboratory tests, alongside partnerships across employee benefits, fintech and fitness.
